(NASDAQ: RVMD) Revolution Medicines's forecast annual revenue growth rate of 71.53% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Revolution Medicines's revenue in 2024 is $11,580,000.On average, 3 Wall Street analysts forecast RVMD's revenue for 2024 to be $2,468,544,526, with the lowest RVMD revenue forecast at $488,801,131, and the highest RVMD revenue forecast at $3,952,569,792. On average, 2 Wall Street analysts forecast RVMD's revenue for 2025 to be $1,726,614,237, with the lowest RVMD revenue forecast at $488,801,131, and the highest RVMD revenue forecast at $2,964,427,344.
In 2026, RVMD is forecast to generate $11,475,957,010 in revenue, with the lowest revenue forecast at $1,599,967,314 and the highest revenue forecast at $21,352,111,397.